Shares of Pluristem Therapeutics Inc. (PSTI) are rising over 24% in pre-market today, after the company announced that the U.S. FDA has cleared the company's Investigational New Drug or IND application for a Phase II study of its PLX cells in the treatment of severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome or ARDS.
The study, titled "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX-PAD for the Treatment of severe COVID-19" would treat 140 adult patients that are intubated and mechanically ventilated and are suffering from respiratory failure and ARDS due to COVID-19.
A Clinical Trial Authorization or CTA has also been filed in Europe for a Phase II COVID-19 trial, with the first European clinical sites planned in Germany and Italy.
The stock has been trading between $2.82 and $13.29 for the past one year, and closed Thursday's trade at $8.49, down 61 cents or 6.70%. PSTI is currently trading at $10.53, up $2.04 or 24.03% in the pre-market session.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.